Icon
+91 94997 68112
Login Register

Alphagan P - (0.15% ; Ophthalmic solution)

Brimonidine Tartrate Allergan
0.15% ; Ophthalmic solution
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
 None
Less Than 5
Less Than 5
Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Yes
***** *** *** *** ***** ** ***** **** ** **** ***(*)(*)**** ******* *,***,*** *** *,***,*** (*** ** ******) ; *******(*** **, ****),*******(*** **, ****) *** *** ************ *********. ***** ******** ******* * ********** **** ***** ********* ** *** ***** ** ***** ***** ******** *** ******* ** **** **, ****. ***** ****** & ***** ***** **** ** *** **** ************ *********. ******* ******** ***** ***** *** *** ******* ** ***** *** ********* ** ****** & *****. ******* ******* ******** *** ********. **** ** ***** ******** *** ***** ****** *** ****.
Alphagan P Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
***** ******* ******* [***(*)*]******* *******[***(*)*] ******* [***(*)*]******* [***(*)*]******* *******
****** **** ** ** **** ** ** **** ** ** **** ** ** *** ********* *** ********* *** ********* **** ** **
***** **** ** ** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ *** [***(*)*] ***, **** ******* ******** ** **** **, ****
****** ** \ ** ***, **** **** ** ** ******** ******** ** *** **, ****
***** ** \ ** ***, **** **** ** ** **** *** ****** *** ****
  1. *****, **** : ***** ***** * *** , ***(*)(*) **** *.**% ********.
  2. ***, **** : ******** ***** * **** ******* ***** ** ******** ***** ** ********.
  3. *****, **** : ******** & ***** ******* * ********** ******** ********* ** ***** ***** ****** *** ** ****, ***** *** **** ** ********** *** *********** ******* ***** ********* **, ****, ** ******* ** ********* ***** ********** *****.
  4. *****, **** : ****** ******** ******** ***** *** ****** ****** **** *.*% & *.**% ******** *** ******* *******,*******,*******,*******,*******.
  5. ***, **** : ******** ***** * **** ******* ****** ** ******** ***** ** ********.
  6. **** **** : ***** ******** ******** ***** *** **** ** ****** **** *.**% ******** *** *** **** ******* ** ******.
  7. *** **** : ******** ***** * **** ******* ***** ** ********** ******* ******** *****. ****-**** : ******** ***** **** * ****** **** ****** & ***** ********* *** ******* ** ******** & ***** **** *** *** ******* **** *****. *** ********** ******** *** ******** ** ******* *******. *** ****: ******* ******* ******** ******** ***** '* ******** ** **** ** ******** ** ****** & *****.
  8. *** **** : ***** ********** ******* ******* '* ******** ***** *** **********
  9. *** **, **** : ********** ********* **** ****** *** *****
  10. *** **, **** : ********* ******** ******** ********* *** **** ** ******.
  11. *** **, **** : ******** **** ********* **** ****** '*** ******** ** ***** **, ****.

Alphagan P - (0.1% ; Ophthalmic Solution)

Brimonidine Tartrate Allergan
0.1% ; Ophthalmic Solution
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
 None
Less Than 5
Less Than 5
Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Yes
Alphagan P Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9
****** **** ** ** **** ** ** **** ** ** **** ** ** *** ********* *** ********* *** ********* **** ** ** *** *********
********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *******
******* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ** ***, **** **** ** ** ******** ******** ** **** **, ****
********* ** \ ** *** **, **** ******* **** ******* *** **** *** *** ****
******* ** \ ** -**- *** ********* ******** ******** ** *** **, ****
  1. *** **, **** : ******** ***** * **** ******* ****** ** ******** ***** ** ********.
  2. *** **, **** : ****** ******** ******** ***** *** ****** ****** **** *.*% & *.**% ******** *** ******* *******,*******,*******,*******,*******.
  3. *** **, **** : ********** ********* **** ******
  4. *** **, **** : ********* ******** ******** ********* *** **** ** ******.
  5. *** **, **** : ******** **** ********* **** ****** '*** ******** ** ***** **, ****.
  6. *** **, **** : ******** ******* ********** **** ********* ** ******* *****.
  7. *** *, **** : ******* ******** ***** ******** *** ******** * ******* *** *** *** *********.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.